Altered expression of the DNA mismatch repair proteins hMLH1 and hMSH2 in cutaneous dysplastic nevi and malignant melanoma

International Journal of Biological Markers

Volumn 20, Issue 1, 2005, Pages 65-68

  Shpitz, B ^a,b   Klein, E ^a,b   Malinger, P ^a,b   Osmolovsky, G ^a,b   Gochberg, S ^a,b   Bomstein, Y ^a,b   Bernheim, J ^a,b  

^a MEIR MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cutaneous melanoma; Dysplastic nevi; Immunohistochemistry; Mismatch repair proteins

Indexed keywords

PROTEIN MLH1; PROTEIN MSH2;

ARTICLE; CONTROLLED STUDY; DYSPLASTIC NEVUS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MELANOMA; MISMATCH REPAIR; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; STAINING; STATISTICAL ANALYSIS;

EID: 18744376968     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2008.4372     Document Type: Article

References (25)

1. Eshleman JR, Markowitz SD. Mismatch repair defects in human carcinogenesis. Hum Molec Genet 1996; 5: 1489-94.
2. Aaltonen LA, Peltomäki P, Leach FS, et al. Clues to the pathogenesis of familial colorectal cancer. Science 1993; 260: 812-6.
3. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58: 5248-57.
4. Peltomäki P. Deficient DNA mismatch repair: a common etiologic factor for colon cancer. Hum Mol Genet 2001; 10: 735-40.
5. Rhyu MS. Molecular mechanisms underlying hereditary nonpolyposis colorectal carcinoma. J Natl Cancer Inst 1996; 88: 240-51.
6. Cawkwell L, Gray S, Murgatroid H, et al. Choice of management strategy for colorectal cancer based on a diagnostic immunohistochemical test for defective mismatch repair. Gut 1999; 45: 409-15.
7. Chaves P, Cruz C, Lage P, et al. Immunohistochemical detection of mismatch repair gene proteins as a useful tool for the identification of colorectal carcinoma with the mutator phenotype. J Pathol 2000; 191: 355-60.
8. Lindor NM, Burgart LJ, Leontovich O, et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 2002; 20: 897-9.
9. Tucker MA, Halpern A, Holly EA, et al. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA 1997; 277: 1439-44.
10. Kanzler MH, Mraz-Gernhard S. Primary cutaneous melanoma and its precursor lesions: diagnostic and therapeutic overview. J Am Acad Dermatol 2001; 45: 260-76.
11. Staebler A, Lax SF, Ellenson LH. Altered expression of hMLH1 and hMSH2 protein in endometrial carcinomas with microsatellite instability. Hum Pathol 2000; 31: 354-8.
12. Markus VA, Madlensky L, Gryfe R, et al. Immunohistochemistry for hMLH1 and hMSH2: a practical test for DNA mismatch repair-deficient tumors. Am J Surg Pathol 1999; 23: 1248-55.
13. Chiaravalli AM, Furlan D, Facco C, et al. Immunohistochemical pattern of hMLH1/hMSH2 in familial and sporadic colorectal, gastric, endometrial and ovarian carcinomas with instability in microsatellite sequences. Virch Arch 2001; 438: 39-48.
14. Hussein MR, Sun M, Tuthill RJ, et al. Comprehensive analysis of 112 melanocytic skin lesions demonstrates microsatellite instability in melanomas and dysplastic nevi, but not in benign nevi. J Clin Pathol 2001; 28: 343-50.
15. Kroiss MM, Vogt T, Schleger J, Landthaler M, Stolz W. Microsatellite instability in malignant melanomas. Acta Derm Venerol 2001; 81: 242-5.
16. Birindelli S, Tragni G, Bartoli C, et al. Detection of microsatellite alterations in the spectrum of melanocytic nevi in patients with or without individual or family history of melanoma. Int J Cancer 2001; 86: 255-61.
17. Hussein MR, Wood GS. hMLH1 and hMSH2 gene mutations are present in radial growth-phase cutaneous melanoma cell lines and can be induced further by ultraviolet-B irradiation. Exp Dermatol 2003; 12: 872-5.
18. Korabiowska M, Viehover M, Schlott T, Berger H, Droese M, Brinck U. Relationship between DNA ploidy-related parameters and the deletions in mismatch repair genes MLH1 and MSH2 in lentigo maligna and malignant melanomas. Arch Dermatol Res 2001; 293: 219-25.
19. Korabiowska M, Brink U, Ruschenberg I, Hönig JF, Stachura J, Droese M. Loss of DNA-mismatch repair gene expression in oral melanomas. Oncol Reports 1999; 6: 921-3.
20. Castiglia D, Pagani E, Alvino E, et al. Biallelic somatic inactivation of the mismatch repair gene MLH1 in a primary skin melanoma. Genes Chromosomes Cancer 2003; 37: 165-75.
21. Hussein MR, Roggero E, Sudilovsky EC, et al. Alterations of mismatch repair protein expression in benign melanocytic nevi, melanocytic dysplastic nevi and cutaneous malignant melanoma. Am J Dermatol 2001; 23: 308-14.
22. Landi MT, Baccarelli A, Tarone RE, et al. DNA repair, dysplastic nevi, and sunlight sensitivity in the development of cutaneous malignant melanoma. J Natl Cancer Inst 2002; 94: 94-101.
23. Wei Q, Lee JE, Gershenwald JE, et al. Repair of UV light-induced DNA damage and risk of cutaneous malignant melanoma. J Natl Cancer Inst 2003; 95: 308-15.
24. Mu D, Tursun M, Duckett DR, Drummond JT, Modrich P, Sancar A. Recognition and repair of compound DNA lesions (base damage and mismatch) by human mismatch repair and excision repair systems. Molec Cell Biol 1997; 17: 760-9.
25. Mellon I, Rajpal G, Koi M, Boland CR, Champe GN. Transcription-coupled repair deficiency and mutations in human mismatch repair genes. Science 1996; 272: 557-60.